214 related articles for article (PubMed ID: 31552622)
1. BZLF1 transcript variants in Epstein-Barr virus-positive epithelial cell lines.
Needham J; Adamson AL
Virus Genes; 2019 Dec; 55(6):779-785. PubMed ID: 31552622
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA miR-BART20-5p stabilizes Epstein-Barr virus latency by directly targeting BZLF1 and BRLF1.
Jung YJ; Choi H; Kim H; Lee SK
J Virol; 2014 Aug; 88(16):9027-37. PubMed ID: 24899173
[TBL] [Abstract][Full Text] [Related]
3. The B-cell specific transcription factor, Oct-2, promotes Epstein-Barr virus latency by inhibiting the viral immediate-early protein, BZLF1.
Robinson AR; Kwek SS; Kenney SC
PLoS Pathog; 2012 Feb; 8(2):e1002516. PubMed ID: 22346751
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-inducible factor-1α plays roles in Epstein-Barr virus's natural life cycle and tumorigenesis by inducing lytic infection through direct binding to the immediate-early BZLF1 gene promoter.
Kraus RJ; Yu X; Cordes BA; Sathiamoorthi S; Iempridee T; Nawandar DM; Ma S; Romero-Masters JC; McChesney KG; Lin Z; Makielski KR; Lee DL; Lambert PF; Johannsen EC; Kenney SC; Mertz JE
PLoS Pathog; 2017 Jun; 13(6):e1006404. PubMed ID: 28617871
[TBL] [Abstract][Full Text] [Related]
5. Cellular differentiation regulator BLIMP1 induces Epstein-Barr virus lytic reactivation in epithelial and B cells by activating transcription from both the R and Z promoters.
Reusch JA; Nawandar DM; Wright KL; Kenney SC; Mertz JE
J Virol; 2015 Feb; 89(3):1731-43. PubMed ID: 25410866
[TBL] [Abstract][Full Text] [Related]
6. B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection.
Romero-Masters JC; Huebner SM; Ohashi M; Bristol JA; Benner BE; Barlow EA; Turk GL; Nelson SE; Baiu DC; Van Sciver N; Ranheim EA; Gumperz J; Sherer NM; Farrell PJ; Johannsen EC; Kenney SC
PLoS Pathog; 2020 Feb; 16(2):e1008365. PubMed ID: 32059024
[TBL] [Abstract][Full Text] [Related]
7. Methylation profiling of Epstein-Barr virus immediate-early gene promoters, BZLF1 and BRLF1 in tumors of epithelial, NK- and B-cell origins.
Li L; Su X; Choi GC; Cao Y; Ambinder RF; Tao Q
BMC Cancer; 2012 Mar; 12():125. PubMed ID: 22458933
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes.
Wen W; Iwakiri D; Yamamoto K; Maruo S; Kanda T; Takada K
J Virol; 2007 Jan; 81(2):1037-42. PubMed ID: 17079287
[TBL] [Abstract][Full Text] [Related]
9. Reactivation of Epstein-Barr Virus by HIF-1α Requires p53.
Kraus RJ; Cordes BA; Sathiamoorthi S; Patel P; Yuan X; Iempridee T; Yu X; Lee DL; Lambert PF; Mertz JE
J Virol; 2020 Aug; 94(18):. PubMed ID: 32641480
[TBL] [Abstract][Full Text] [Related]
10. Shutoff of BZLF1 gene expression is necessary for immortalization of primary B cells by Epstein-Barr virus.
Yu X; McCarthy PJ; Wang Z; Gorlen DA; Mertz JE
J Virol; 2012 Aug; 86(15):8086-96. PubMed ID: 22623769
[TBL] [Abstract][Full Text] [Related]
11. Expression of Epstein-Barr virus lytic gene BRLF1 in nasopharyngeal carcinoma: potential use in diagnosis.
Feng P; Ren EC; Liu D; Chan SH; Hu H
J Gen Virol; 2000 Oct; 81(Pt 10):2417-2423. PubMed ID: 10993929
[TBL] [Abstract][Full Text] [Related]
12. A cancer-associated Epstein-Barr virus BZLF1 promoter variant enhances lytic infection.
Bristol JA; Djavadian R; Albright ER; Coleman CB; Ohashi M; Hayes M; Romero-Masters JC; Barlow EA; Farrell PJ; Rochford R; Kalejta RF; Johannsen EC; Kenney SC
PLoS Pathog; 2018 Jul; 14(7):e1007179. PubMed ID: 30052684
[TBL] [Abstract][Full Text] [Related]
13. Discrete alterations in the BZLF1 promoter in tumor and non-tumor-associated Epstein-Barr virus.
Gutiérrez MI; Ibrahim MM; Dale JK; Greiner TC; Straus SE; Bhatia K
J Natl Cancer Inst; 2002 Dec; 94(23):1757-63. PubMed ID: 12464647
[TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor beta 1 stimulates expression of the Epstein-Barr virus BZLF1 immediate-early gene product ZEBRA by an indirect mechanism which requires the MAPK kinase pathway.
Fahmi H; Cochet C; Hmama Z; Opolon P; Joab I
J Virol; 2000 Jul; 74(13):5810-8. PubMed ID: 10846060
[TBL] [Abstract][Full Text] [Related]
15. The Long and Complicated Relationship between Epstein-Barr Virus and Epithelial Cells.
Hutt-Fletcher LM
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795426
[TBL] [Abstract][Full Text] [Related]
16. Ceramide promotes lytic reactivation of Epstein-Barr virus in gastric carcinoma.
Kim JY; Min YJ; Lee M-H; An YR; Ashktorab H; Smoot DT; Kwon SW; Lee SK
J Virol; 2024 Feb; 98(2):e0177623. PubMed ID: 38197630
[TBL] [Abstract][Full Text] [Related]
17. Use of adenovirus vectors expressing Epstein-Barr virus (EBV) immediate-early protein BZLF1 or BRLF1 to treat EBV-positive tumors.
Feng WH; Westphal E; Mauser A; Raab-Traub N; Gulley ML; Busson P; Kenney SC
J Virol; 2002 Nov; 76(21):10951-9. PubMed ID: 12368338
[TBL] [Abstract][Full Text] [Related]
18. Viral genome methylation differentially affects the ability of BZLF1 versus BRLF1 to activate Epstein-Barr virus lytic gene expression and viral replication.
Wille CK; Nawandar DM; Panfil AR; Ko MM; Hagemeier SR; Kenney SC
J Virol; 2013 Jan; 87(2):935-50. PubMed ID: 23135711
[TBL] [Abstract][Full Text] [Related]
19. BZLF1 governs CpG-methylated chromatin of Epstein-Barr Virus reversing epigenetic repression.
Woellmer A; Arteaga-Salas JM; Hammerschmidt W
PLoS Pathog; 2012 Sep; 8(9):e1002902. PubMed ID: 22969425
[TBL] [Abstract][Full Text] [Related]
20. PARP1 restricts Epstein Barr Virus lytic reactivation by binding the BZLF1 promoter.
Lupey-Green LN; Moquin SA; Martin KA; McDevitt SM; Hulse M; Caruso LB; Pomerantz RT; Miranda JL; Tempera I
Virology; 2017 Jul; 507():220-230. PubMed ID: 28456021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
